National Institutes of Health, National Institute Mental of Health, Bethesda, Maryland, USA.
AIDS. 2012 May 15;26(8):959-69. doi: 10.1097/QAD.0b013e328352cee7.
To evaluate baseline T-cell activation and neurodevelopmental outcomes over time in a cohort of perinatally HIV-infected (PHIV-infected) children with severe disease.
Pediatric AIDS Clinical Trials Group protocol 366 (PACTG 366) was a partially randomized, open-label, multicenter 96-week antiretroviral treatment-algorithm study. Neurodevelopmental status, measured by age-dependent evaluations (Bayley scales of infant development-II; Wechsler preschool and primary scale of intelligence-revised; Wechsler intelligence scale for children-III), was a secondary outcome.
Linear mixed models were used to assess the baseline and follow-up neurodevelopmental outcomes in relation to immune activation, measured by CD38 and human leukocyte antigen (HLA) DR expression on peripheral CD4(+) and CD8(+) T cells at study baseline. Models were adjusted for age, sex, race/ethnicity, baseline viral load, baseline CD4%, cytomegalovirus (CMV) infection status at entry, study treatment arms, central nervous system penetrance score of antiretroviral regimen at entry, and viral load response 16 weeks postentry.
Among 126 PACTG 366 enrollees who were at least 1 year old and had both immune activation and age-appropriate neurodevelopmental assessments at baseline, 80 (63%) were black non-Hispanic, 71 (56%) males, 122 (97%) were on antiretrovirals, and 45 (36%) were in Centers for Disease Control and Prevention (CDC) disease category C at entry. CD4(+)CD38(+)HLADR(+)%, CD4(+)CD38(-)HLADR(+)%, and CD8(+)CD38(+)HLADR(+)% were positively associated with full-scale Intelligence Quotient scores (FSIQ) (slope = 0.18, 0.70, and 0.15, respectively; P = 0.02, 0.03, and 0.04, respectively). CD4(+)CD38(+)HLADR(-)% was negatively associated with FSIQ (slope = -0.16, P = 0.01).
Contrary to HIV-infected adults, in PHIV-infected children higher CD4(+)CD38(+)HLADR(+)% may be associated with a neuroprotective effect and higher percentage of CD4(+)CD38(+) but HLADR(-) T cells may be deleterious.
评估在一组患有严重疾病的围生期感染人类免疫缺陷病毒(PHIV 感染)的儿童中,基线 T 细胞激活与神经发育结局随时间的变化。
儿科艾滋病临床试验组方案 366(PACTG 366)是一项部分随机、开放标签、多中心 96 周抗逆转录病毒治疗算法研究。神经发育状况通过年龄依赖性评估(贝利婴幼儿发展量表 II;韦氏学前和初级智力量表修订版;韦氏儿童智力量表 III)进行测量,是次要结局。
线性混合模型用于评估基线和随访神经发育结局与免疫激活的关系,免疫激活通过外周血 CD4+和 CD8+T 细胞上 CD38 和人类白细胞抗原(HLA)DR 的表达来测量。模型调整了年龄、性别、种族/民族、基线病毒载量、入组时巨细胞病毒(CMV)感染状态、研究治疗组、入组时抗逆转录病毒方案的中枢神经系统穿透评分以及入组后 16 周时的病毒载量反应。
在至少 1 岁且基线时有免疫激活和适合年龄的神经发育评估的 126 名 PACTG 366 入组者中,80 名(63%)为黑非西班牙裔,71 名(56%)为男性,122 名(97%)正在接受抗逆转录病毒治疗,45 名(36%)在入组时处于疾病预防控制中心(CDC)疾病分类 C 期。CD4+CD38+HLADR+%、CD4+CD38(-)HLADR+%和 CD8+CD38+HLADR+%与全量表智商(FSIQ)呈正相关(斜率分别为 0.18、0.70 和 0.15;P 值分别为 0.02、0.03 和 0.04)。CD4+CD38+HLADR(-)%与 FSIQ 呈负相关(斜率为 -0.16,P = 0.01)。
与 HIV 感染的成年人不同,在 PHIV 感染的儿童中,较高的 CD4+CD38+HLADR+%可能与神经保护作用相关,而较高比例的 CD4+CD38+但 HLADR(-)T 细胞可能具有有害作用。